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Abstract
Aims/hypothesis Most pregnant women with type 1 diabetes
mellitus achieve HbA1c targets; however, macrosomia
remains prevalent and better pregnancy glycaemic markers
are therefore needed. 1,5-Anhydroglucitol (1,5-AG) is a short-
term marker of glycaemia, reflecting a period of 1 to 2 weeks.
Its excretion rate depends on the renal glucose threshold and
thus it is unclear whether it may be used in pregnant type 1
diabetes women.We evaluated 1,5-AG as a glycaemic marker
and birthweight predictor in pregnant women with type 1
diabetes, and compared its performance with HbA1c.
Methods 1,5-AG and HbA1c were measured in 82 pregnant
women with type 1 diabetes. In addition, 58 continuous
glucose monitoring system (CGMS) records were available.
Macrosomia was defined as birthweight >90th centile. The
data were analysed with Pearson’s correlations, and linear
and logistic regression models. Receiver operating charac-
teristic (ROC) analysis was used to evaluate third trimester
1,5-AG as a predictor of macrosomia.
Results Unlike HbA1c, 1,5-AG strongly correlated with
CGMS indices: the AUC above 7.8 mmol/l (r=−0.66; p<
0.001), average maximum glucose (r=−0.58; p<0.001) and
mean glucose (r=−0.54; p<0.001). In the third trimester, 1,5-
AG was the strongest predictor of macrosomia, with ROC
AUC 0.81 (95% CI 0.70, 0.89). In contrast, HbA1c in the third
trimester had a ROC AUC of 0.69 (95% CI 0.58, 0.81). The
best discrimination was achieved when both markers were used
jointly, yielding a ROC AUC of 0.84 (95% CI 0.76, 0.93).
Conclusions/interpretation In pregnant women with type 1
diabetes, 1,5-AG is a better glycaemic marker than HbA1c, as
assessed by CGMS. A decreased third trimester 1,5-AG level,
either singly or withHbA1c, is a strong predictor ofmacrosomia.
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Abbreviations
1,5-AG 1,5-Anhydroglucitol
CGMS Continuous glucose monitoring system
NRI Net reclassification improvement
ROC Receiver operating characteristic
SMBG Self-monitoring of blood glucose
Introduction
Pregnancy complicated by type 1 diabetes mellitus requires
tight glycaemic control. Clinical guidelines include HbA1c
targets for affected women [1]. A growing number of type 1
diabetic women achieve the recommended HbA1c goal; how-
ever, the prevalence of macrosomia remains high [2–4]. This
may be because HbA1c, a long-term glycaemic marker, does
not reflect short excursions [5]. Moreover, glucose peaks are
frequently missed in the conventional self-monitoring of
blood glucose (SMBG) [5]. Continuous glucose monitoring
systems (CGMS) are still expensive, time-consuming and
invasive [6]. An association between levels of fructosamine,
a short-term glycaemic marker, and birthweight has been
described in pregnant women with type 1 diabetes [7]; how-
ever, it is not widely used in clinical practice.
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1,5-Anhydroglucitol (1,5-AG) is a monosaccharide,
which is sometimes used as a short-term marker of glycae-
mic excursions, particularly postprandial ones [8]. In con-
trast to HbA1c, it reflects changes in glycaemic control over
the preceding 1 to 2 weeks [9]. Due to its competition with
other monosaccharides for reabsorption in the proximal
renal tubule, the 1,5-AG excretion rate depends on the renal
threshold for glucose [10]. As this threshold is decreased
during pregnancy, the clinical value of using 1,5-AG to
evaluate glycaemic control in pregnant women with type 1
is currently not established.
We evaluated the association of serum 1,5-AG and
HbA1c with CGMS indices, as well as the performance of
1,5-AG and HbA1c levels in predicting macrosomia.
Methods
Patients Between 2008 and 2012 we contacted 98 consec-
utively presenting pregnant type 1 diabetic women receiving
care in the Department of Metabolic Diseases, Krakow,
Poland. Of the patients contacted, 92 agreed to participate
and 86 completed follow-up until delivery. Since 1,5-AG
levels can be altered in chronic renal and liver diseases, we
excluded two patients because of hepatic dysfunction; none
of the participants had stage 3 or higher chronic kidney
disease. In addition, two women who miscarried were not
included. Thus, the study group consisted of 82 women
whose characteristics are shown in Table 1. The proto-
col was approved by the Bioethical Committee of the
Table 1 Maternal and neonatal characteristics of the entire study group and subgroups defined by neonatal birthweight
Total (mean, median, SD) Grouped by birthweight (mean, median, SD)
Characteristic <90th centile >90th centile p value
n = 82 n = 54 n = 28 NA
Maternal
Maternal age (years) 29.6 29.0 4.5 29.5 29.1 4.6 30.0 30.0 4.4 0.62
Pre-pregnancy BMI (kg/m2) 23.8 23.2 4.3 23.7 23.0 4.6 24.0 23.5 3.7 0.75
T1DM duration (years) 12.3 12.0 7.3 12.6 11.0 7.6 12.1 12.0 7.2 0.77
Insulin regimen
MDI (n) 2 1 1 NA
CSII (n) 80 53 27 NA
MG (mmol/l)
Second trimester 5.88 5.8 0.83 5.62 5.5 0.58 6.35 6.5 0.97 0.002
Third trimester 5.83 5.8 0.79 5.67 5.5 0.72 6.13 6.0 0.83 0.015
MMG (mmol/l)
Second trimester 9.34 9.2 1.86 8.56 8.70 1.86 9.87 9.78 1.47 0.001
Third trimester 8.90 8.8 1.70 8.68 8.21 1.98 9.37 9.60 2.06 0.02
HbA1c (%)
Second trimester 5.5 5.4 0.7 5.3 5.2 0.7 5.8 5.8 0.7 0.001
Third trimester 5.4 5.4 0.7 5.2 5.2 0.6 5.8 5.7 0.7 0.003
HbA1c (mmol/mol)
Second trimester 37 36 7.2 34 33 7.1 40 40 7.2 NA
Third trimester 36 36 7.1 33 33 6.5 40 39 7.2 NA
1,5-AG (μmol/l)
Second trimester 29.40 25.71 12.24 33.06 29.17 13.47 23.57 22.65 5.51 0.001
Third trimester 30.18 26.33 11.02 34.29 30.08 11.63 23.54 22.04 5.51 <0.001
Neonatal
GA at birth (weeks) 38.6 39 1.6 38.6 39 1.7 38.7 39 1.4 0.79
Birthweight (g) 3,501 3,520 647.3 3,148 3,225 463.5 4,205 4,250 280.8 <0.001
Birthweight (centile) 64.6 75 31 45.6 50 25.1 97.3 98 2.4 <0.001
Quantitative traits are presented as mean, median and standard deviation
p values compare the macrosomic and normal weight subgroup and were calculated with Student’s t test or Mann–Whitney U test
CSII, continuous subcutaneous insulin infusion; GA, gestational age; MDI, multiple daily injection; MG, mean glucose; MMG, mean maximum
glucose; NA, not applicable; T1DM, type 1 diabetes mellitus
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Jagiellonian University. Written informed consent was
obtained from all participants.
Clinical measurements In each trimester, the serum 1,5-AG
concentration was measured immuno-enzymatically with a
kit (1,5-AG ELISA Kit; Cusabio, Wuhan, China). The intra-
and inter-assay coefficients of variation were <1.8% and
0.9% to 4.6%, respectively. HbA1c levels were also assessed
in each trimester, using high-performance liquid chromatog-
raphy (Bio-Rad, Strasbourg, France). In 58 women (12, 22
and 24 in the consecutive trimesters), the results of CGMS
were analysed for a 7 day period before blood collection for
1,5-AG and HbA1c measurement. Mean glycaemia, its
standard deviation, mean maximum glycaemia (defined
as the average daily maximum over 7 days), 7 day
mean AUC above 7.8 mmol/l (AUC-7.8) and 7 day
mean AUC below 3.1 mmol/l (AUC-3.1) were calculat-
ed using CGMS software (Medtronic, Minneapolis, MN,
USA). Eight-point SMBG profiles were performed daily
to calculate mean glucose and mean maximum glucose
for the analysis of birthweight and macrosomia in the
82 pregnancies.
Statistical analysis The association of serum 1,5-AG and
HbA1c with CGMS indices, as well as the performance of
1,5-AG and HbA1c levels in predicting macrosomia, were
examined. The relationship between outcomes (CGMS in-
dices or birthweight) and predictors (1,5-AG or HbA1c) was
analysed with Pearson correlations and multiple regression.
We controlled for possible confounding by gestational age,
pre-pregnancy BMI or maternal age. Skewed data were log-
transformed. Logistic regression, receiver operating charac-
teristic (ROC) analysis and continuous net reclassification
improvement (NRI) [11] were used to evaluate 1,5-AG and
HbA1c as predictors of macrosomia, defined as a neonatal
birthweight >90th percentile (sex-specific) in the Polish
population. Statistical calculations were performed with
MedCalc 9.3.8 (MedCalc Software, Ostend, Belgium) and
SAS 9.3 (SAS Institute, Cary, NC, USA). Values of p<0.05
were considered significant.
Results
Glycemic control The group of type 1 diabetic women
examined by us had excellent glycaemic control, as
defined by HbA1c targets. Mean HbA1c levels were
5.8±0.9%, 5.5±0.7% and 5.4±0.7% (40±10, 37±7 and
36±7 mmol/mol) in first, second and third trimesters
respectively. There was no difference in mean 1,5-AG
levels between consecutive pregnancy trimesters (30.0±
11.0, 29.4±12.2, 30.0±11.0 μmol/l; 4.9±1.8, 4.8±2 and
4.9±1.8 μg/ml; p=0.4, respectively).
Association of HbA1c and 1,5-AG with CGMS To evaluate
1,5-AG and HbA1c as markers of glucose levels, we used
CGMS measurements from 56 women at various gestational
ages. Interestingly, there was no correlation between 1,5-AG
and HbA1c (r=−0.07; p=0.57). 1,5-AG correlated strongly
with CGMS-based mean glucose (r=−0.54; p<0.001), and
with a metric of glucose variability (amplitude)—standard
deviation (r=0.60; p<0.001). In addition, 1,5-AG correlated
with two metrics of hyperglycaemia: average maximum glu-
cose (r=−0.58; p<0.001) and AUC-7.8 (r=−0.66; p<0.001).
It did not correlate (r=0.05, p=0.70) with hypoglycaemia
(AUC-3.1). HbA1c was weakly correlated with mean glucose
(r=0.34; p=0.01), but not with standard deviation (r=0.17; p=
0.23), mean maximum glucose (r=0.2; p=0.14), AUC-7.8 (r=
0.22; p=0.10) and AUC-3.1 (r=−0.23; p=0.10). The pattern
of correlations was not affected when the analysis was restrict-
ed to a particular trimester. In regression models, in which
CGMS indices (except AUC-3.1) were used as dependent
variables, 1,5-AG was always statistically independent of
HbA1c (p<0.001 in each model).
Predicting macrosomia with 1,5-AG and HbA1c We subse-
quently evaluated 1,5-AG in 82 women as a risk marker of
clinical outcome, birthweight and macrosomia. In 28 (34%)
pregnancies, macrosomia was diagnosed. Interestingly, in 22
mothers of macrosomic newborns (80% of macrosomia cases)
third trimester HbA1c was <6.0% (42 mmol/mol). The mean
second and third trimester 1,5-AG concentrations (Table 1)
were significantly lower in mothers of macrosomic babies
(p=0.001 and p<0.001 for the second and third trimester,
respectively). The correlation coefficient of 1,5-AG levels with
birthweight was r=−0.44 (p<0.001) for the second and r=
−0.58 (p<0.001) for the third trimester. The corresponding
coefficients for second and third trimester HbA1c levels were
0.29 (p=0.014) and 0.32 (p=0.005), respectively. In the multi-
variate linear regression model, the 1,5-AG level, either in the
second or third trimester, was associated with birthweight inde-
pendently (p<0.001) of HbA1c, after adjusting for confounders.
The third trimester 1,5-AG value, the strongest predictor of
birthweight, was evaluated in logistic regression as a risk
marker of macrosomia. The relative odds of macrosomia per
1 μg/ml (6.1μmol/l) decrease in 1,5-AGwas 3.0 (95%CI 1.6,
5.8; p=0.001). In ROC analysis the AUC reached 0.81 (95%
CI 0.70, 0.89). The optimum sensitivity, specificity, and
corresponding positive and negative predictive values were
96.3%, 56%, 55% and 96.6%, respectively at 4.76 μg/ml
(29.0 μmol/l) as cut-off value for 1,5-AG (Fig. 1). Addition-
ally, the AUC of 1,5-AG in the second trimester was 0.75
(95% CI 0.64, 0.86). In comparison, the AUC of HbA1c in the
third and second trimester was 0.69 (95% CI 0.58, 0.81) and
0.71 (95% CI 0.59, 0.83), respectively. The difference be-
tween the AUC of 1,5-AG and HbA1c (0.81 vs 0.69) was
not statistically significant (p=0.15); however, another
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discrimination measure, NRI [11], was 0.49 (95% CI 0.05,
0.93; p=0.028) in favour of 1,5-AG.
Since HbA1c and 1,5-AG are independently associat-
ed with birthweight, we used the third trimester
markers 1,5-AG in combination with HbA1c to predict
macrosomia. This model had a substantially improved
AUC of 0.84 (95% CI 0.76, 0.93), which was signifi-
cantly better than HbA1c alone (p=0.009). The NRI
was 0.94 (95% CI 0.56, 1.31; p<0.001). The addition
of second trimester markers, maternal age and BMI did
not alter the results and did not significantly improve
prediction. Using the predictive score derived from the
model variables 1.2×(HbA1c [%])− (1,5-AG [μg/ml]) or
(HbA1c [mmol/mol])− 1.5× (1,5-AG [μmol/l]), we
obtained optimum sensitivity, specificity, and positive
and negative predictive values of 85.7%, 71.4%,
63.2% and 89.7%, respectively, where score values
≥2.14 (or ≥−4.13, when molar concentrations are used)
indicated risk of macrosomia with relative odds of 2.8
(95% CI 1.6, 4.8; p<0.001).
Discussion
In our study of pregnant women with type 1 diabetes
mellitus, levels of 1,5-AG, a short-term glycaemic mark-
er that, unlike HbA1c, captures episodes of hyperglycae-
mia, were strongly correlated with indices derived from
CGMS. The observed negative correlations between 1,5-
AG levels and CGMS metrics are in agreement with
earlier studies involving non-pregnant diabetic partici-
pants [8]. It has also been previously shown that HbA1c
levels did not correlate well with maternal glucose pro-
files measured with CGMS [5]. This seems to explain
the high rate of adverse pregnancy outcomes observed
earlier [2–4] and in this study, despite patients achieving
the recommended HbA1c values.
This finding could be of clinical importance, as we have
shown for the first time that 1,5-AG provides insight into
short-term glycaemic control in pregnant women with type
1 diabetes. Its use may improve the assessment of whether
insulin dosage modifications are necessary, eventually help-
ing improve pregnancy outcomes. Currently, patients with
type 1 diabetes are mainly monitored by daily SMBG in
combination with HbA1c. 1,5-AG, which responds rapidly
to changes in glucose profile, may facilitate treatment
adjustments, providing an accurate, rapid, possibly cost-
effective and practical additional or even alternative tool to
HbA1c, and one that probably would also be more reliable
and objective than SMBG.
Another new finding was that third trimester 1,5-AG
levels appeared to be a strong predictor of macrosomia
and, as indicated by AUC values in ROC analysis,
performed better than HbA1c. It should be noted that
most mothers of macrosomic babies met HbA1c-based
criteria of glycaemic control. The high risk of macro-
somia in such patients may be explained by glucose
excursions that were undetected with HbA1c, but were
reflected in their 1,5-AG levels. Indeed, 1,5-AG was
strongly associated with CGMS AUC-7.8, standard de-
viation and average maximum glycaemia. 1,5-AG could
therefore be a particularly suitable marker in patients
achieving HbA1c targets. Although 1,5-AG singly was
superior to HbA1c in predicting risk of macrosomia,
even better results were achieved when both markers
were used jointly. Since 1,5-AG and HbA1c were un-
correlated, the best discriminative accuracy was
achieved when information from both these markers
was combined in the proposed risk index. A possible
shortcoming of our study is that two short-term meas-
ures, 1,5-AG and CGMS, were analysed together with a
long-term measure, HbA1c. In addition, the difference in
the prediction power of macrosomia risk between 1,5-
AG and HbA1c was rather moderate. Future clinical
Fig. 1 ROC curve analysis for
third trimester maternal 1,5-AG.
(a) ROC curve illustrating the
accuracy of 1,5-AG in predicting
neonate macrosomia. Circle,
optimum value; diagonal dotted
line, the null value of ROC
curve. (b) Sensitivity (black) and
specificity (grey) plotted against
cut-off value of 1,5-AG
concentration
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studies targeting HbA1c and 1,5-AG therapeutic goals in
pregnant women with type 1 diabetes would be of
tremendous interest.
In spite of earlier concerns [10] that the decreased renal
threshold for glucose in pregnancy might lower the 1,5-AG
level and potentially decrease its ability to differentiate well-
and poorly controlled diabetes, 1,5-AG in our study appeared
to be a very good marker of glycaemia in pregnant women
with type 1 diabetes. During pregnancy, our patients achieved
excellent glycaemic targets, which would have acted in the
opposite direction to that of an altered renal threshold, i.e. by
increasing the 1,5-AG level. Eventually, 1,5-AG remained
very sensitive to hyperglycaemia. Its performance in pregnant
women with other types of diabetes, who may differ not only
by the degree of metabolic control but also in terms of gly-
caemic fluctuations, requires further evaluation.
In summary, 1,5-AG performs better than HbA1c as a tool
for monitoring the glucose profile in pregnancies complicated
by type 1 diabetes. Its decreased third trimester level is a very
valuable predictor of macrosomia, particularly considered
together with HbA1c. The determination of 1,5-AG should
be considered for clinical use in type 1 diabetic pregnancies.
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